Core Points - Neurocrine Biosciences held its 2025 R&D Day, emphasizing the importance of the event for stakeholders [1] - The event featured key executives including the CEO, Chief Medical Officer, and Chief Scientific Officer, highlighting the leadership team's experience [2][3] - Dr. John Krystal, a prominent figure in neurology and psychiatry, participated in the event, indicating the company's commitment to collaboration with leading experts [3]

Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic Modalities Reviewed Positive Data Across Late-Stage Neuropsychiatry Pipeline Including Osavampator and Direclidine; Topline Phase 3 Data from Both Programs Expected in 2027 Announced Expansion of CRF Platform as Foundation of New Class of Medicines for Metabolic Diseases, Including Obesity SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Neurocrine B ...

December 16, 2025 1 Forward-Looking Statements Neurocrine Biosciences R&D Day 2025 In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the conti ...

SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) in San Diego. Neurocrine management will highlight the Company's ongoing R&D transformation and its growing neuroscience pipeline. The event will also feature a discussion with key opinion leader John Krystal, M.D., Professor of Translational Research and Professor of Psychiatry, of Neuroscie ...

Today's Spotlight BREAKING: Carvana, Comfort Systems, CRH To Join S&P 500 Neurocrine Biosciences (NBIX) is this week's Big Cap 20 pick to watch, as the drug stock is back inside a 5% buy zone from a recent entry. The biotech has a few flagship drugs. Among them are Crenessity, which treats classic congenital adrenal hyperplasia. It also has Ingrezza, a treatment for the movement disorders known as tardive dyskinesia and chorea,… MarketSurge Cyber Week Sale This week, save over 80% on MarketSurge—get 2 month ...

PresentationSo it's been quite a year. So I would love to turn it over to Matt for just a few opening remarks on, I guess, a reflection on what's been to say the least, an interesting year, both for Neurocrine and for the biotech space, we're at large.Well, let's kick things off. This is David Amsellem from the Piper Sandler biopharma research team. We're delighted to have Neurocrine here. We have Matt Abernethy, CFO. We have Eric Benevich, Chief Commercial Officer. We have Todd Tushla, director of Investor ...

Neurocrine Biosciences (NasdaqGS:NBIX) FY Conference December 02, 2025 09:30 AM ET Company ParticipantsEric Benevich - CCOMatt Abernethy - CFOConference Call ParticipantsDavid Amsellem - AnalystDavid AmsellemAll right.Matt AbernethyOkay, we're live now.David AmsellemWe are live.Matt AbernethyThat's awesome.David AmsellemAll right.Matt AbernethyOutside chat.David AmsellemLet's kick things off. This is David Amsellem from the Piper Sandler Biopharma Research Team. We're delighted to have Neurocrine here. We h ...

Core Insights - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company focused on neurological and endocrine-related disorders, known for its innovative therapies and strong market presence [1] - Canaccord Genuity has reiterated a "Buy" rating for NBIX, indicating confidence in the company's future performance, while suggesting a "hold" action for investors [2] - Capital Fund Management S.A. increased its holdings in NBIX by 15.9%, now owning 203,628 shares valued at approximately $25.6 million, reflecting belief in the company's growth potential [3] - Other institutional investors, such as Geneos Wealth Management Inc. and WPG Advisers LLC, have also adjusted their positions, indicating growing interest in NBIX [4] - The current stock price of NBIX is $151.58, reflecting a 5.61% increase, with a market capitalization of approximately $15.07 billion [5][6]

Core Insights - Growth investors are attracted to stocks with above-average financial growth, but identifying such stocks can be challenging due to their inherent risks and volatility [1] Group 1: Company Overview - Neurocrine Biosciences (NBIX) is highlighted as a recommended growth stock based on the Zacks Growth Style Score, which evaluates a company's growth potential beyond traditional metrics [2] - The company currently holds a favorable Growth Score and a top Zacks Rank, indicating strong investment potential [2] Group 2: Earnings Growth - Neurocrine's historical EPS growth rate stands at 16.2%, but the projected EPS growth for this year is significantly higher at 99.6%, surpassing the industry average of 26% [5] - This exceptional earnings growth is a key factor that attracts investor interest and suggests strong future stock price gains [4] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Neurocrine is reported at 35.4%, which is substantially higher than the industry average of 3.2% [6] - Over the past 3-5 years, the company's annualized cash flow growth rate has been 39.5%, compared to the industry average of 6.9%, indicating robust financial health [7] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Neurocrine have been revised upward, with the Zacks Consensus Estimate increasing by 15.4% over the past month [9] - Positive trends in earnings estimate revisions are correlated with near-term stock price movements, further validating the stock's potential [8] Group 5: Investment Positioning - Neurocrine has achieved a Zacks Rank 1 (Strong Buy) due to favorable earnings estimate revisions and a Growth Score of B, positioning it well for outperformance in the market [11]

Core Insights - Neurocrine Biosciences (NBIX) has experienced a mixed performance, with shares increasing approximately 12% [1] Company Performance - The stock performance of Neurocrine has slightly outperformed expectations compared to analysts' predictions [1]